Table 4.
Effect of ceftriaxone plus sulbactam with VRP1034 on xanthine oxidase (XO) and gluathione s transferase (GST)in cadmium exposed group after 21 days of treatment.
| Groups | Plasma (nmol/min/ml) | Liver (nmole/min/g tissue) | Kidney (nmole/min/g tissue) | Brain (nmol/min/g tissue) | ||||
|---|---|---|---|---|---|---|---|---|
| XO | GST | XO | GST | XO | GST | XO | GST | |
| Control group | 135.4±8.56 | 14.33±1.52 | 44.10±2.65 | 25.12±1.87 | 58.84±4.23 | 36.41±3.78 | 111.02±7.49 | 9.11±1.02 |
| Cd exposed group | 296.3±10.22*** | 18.96±1.10*** | 87.33±6.02*** | 51.05±2.64*** | 64.20±3.63* | 42.16±2.81*** | 144.89±9.48*** | 13.40±1.47*** |
| Ceftriaxone plus sulbactam with VRP1034 group | 168.7±14.31*** | 13.74±0.55*** | 71.82±4.49*** | 37.0±2.09*** | 56.22±1.77*** | 40.33±1.59ns | 139.45±8.80ns | 10.00±1.12*** |
All data are Mean ± SD of each group. The XO and GST levels were expressed in the plasma (µmole/min/ml) whereas in the tissues (µmol/g tissue). Newman keuls test was performed for statistical significance between control group vs Cd exposed group and Cd exposed group vs ceftriaxone plus sulbactam with VRP1034 treated group.
***
Where p<0.001 (highly significant)
**
p<0.01(significant)
*
p<0.05 (significant)
Ns
p>0.05 (non significant).